Cingulate Inc. (CING)
- Previous Close
0.8653 - Open
0.8684 - Bid 0.8484 x 100
- Ask 0.9216 x 100
- Day's Range
0.8400 - 0.9299 - 52 Week Range
0.7500 - 23.4000 - Volume
8,654 - Avg. Volume
311,646 - Market Cap (intraday)
5.322M - Beta (5Y Monthly) -0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-26.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.50
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
www.cingulate.comRecent News: CING
Performance Overview: CING
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CING
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CING
Valuation Measures
Market Cap
5.32M
Enterprise Value
8.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-190.98%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.53M
Diluted EPS (ttm)
-26.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
52.42k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.36M